Medscape is available in 5 Language Editions – Choose your Edition here.


Chronic Myelogenous Leukemia (CML) Treatment & Management

  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
Updated: Apr 14, 2016

Approach Considerations

The goals of treatment of chronic myelogenous leukemia (CML) are threefold and have changed markedly in the past 10 years. They are as follows:

  1. Hematologic remission (normal complete blood cell count (CBC) and physical examination (ie, no organomegaly)
  2. Cytogenetic remission (normal chromosome returns with 0% Philadelphia chromosome–positive (Ph+) cells)
  3. Molecular remission (negative polymerase chain reaction [PCR] result for the mutational BCR/ABL mRNA), which represents an attempt for cure and prolongation of patient survival

Typically, CML has three clinical phases: an initial chronic phase, during which the disease process is easily controlled; then a transitional and unstable course (accelerated phase); and, finally, a more aggressive course (blast crisis), which is usually fatal. In all three phases, supportive therapy with transfusions of red blood cells or platelets may be used to relieve symptoms and improve quality of life.

In Western countries, 90% of patients with CML are diagnosed in the chronic phase. These patients’ white blood cell (WBC) count is usually controlled with medication (hematologic remission). The major goal of treatment during this phase is to control symptoms and complications resulting from anemia, thrombocytopenia, leukocytosis, and splenomegaly. The standard treatment of choice is now imatinib mesylate (Gleevec), which is a specific small-molecule inhibitor of BCR/ABL in all phases of CML.

The chronic phase varies in duration, depending on the maintenance therapy used: it usually lasts 2-3 years with hydroxyurea (Hydrea) or busulfan therapy, but it may last for longer than 9.5 years in patients who respond well to interferon-alfa therapy. Furthermore, the advent of imatinib mesylate has dramatically improved the duration of hematologic and, indeed, cytogenetic remissions.

Some patients with CML progress to a transitional or accelerated phase, which may last for several months. The survival of patients diagnosed in this phase is 1-1.5 years. This phase is characterized by poor control of the blood counts with myelosuppressive medication and the appearance of peripheral blast cells (≥15%), promyelocytes (≥30%), basophils (≥20%), and platelet counts less than 100,000 cells/μL unrelated to therapy.

Many of the treatment decisions in CML, including possible bone marrow or stem cell transplantation[15] and investigative options for younger patients, are extremely complex and in constant flux. Individualized decisions should be made in conjunction with consultation with physicians familiar with the recent literature. New agents that are currently under study may prolong the survival of patients with CML and offer the possibility of eventual cure. Physicians should refer their patients to tertiary care centers for clinical trials involving these therapies.

For more information, see the Medscape articles Chronic Myelogenous Leukemia Treatment Protocols and Chronic Myelogenous Leukemia (CML) Guidelines


Imatinib Mesylate

Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor that inhibits the abnormal bcr-abl tyrosine kinase created by the Philadelphia (Ph1) chromosome translocation abnormality. Imatinib inhibits proliferation and induces apoptosis in cells positive for BCR/ABL.[3, 4, 7, 16, 17]

With imatinib at 400 mg/day orally in patients with newly diagnosed Ph1-positive CML in the chronic phase, the complete cytogenetic response rate is 70% and the estimated 3-year survival rate is 94%. With higher doses of 800 mg/day, the complete cytogenetic response rate increases to 98%, the major molecular response rate is 70%, and the complete molecular response rate is 40-50%.

Santos et al reported that the use of erythropoietic-stimulating growth factors with imatinib did not impact response rates or survival but increased risk for thrombosis. The presence of severe anemia in these patients was associated with worse survival and response.[18]

Kantarjian et al reported that in patients in the chronic phase who had failure or intolerance of interferon treatment, treatment with imatinib resulted in a complete hematologic response in 430 of 454 patients (95%), with a major cytogenetic response (ie, 0-35% of cells in metaphase positive for the Ph1 chromosome) in 60% of patients; 41% had a total response.[4] Among the study patients with features of accelerated-phase CML (n=17), rates of cytogenetic and hematologic responses were 59% and 88%, respectively and among those with features of blastic-phase CML (n=12), rates were 75% and 92%, respectively.

Talpaz et al reported that among 235 patients with accelerated-phase CML, treatment with imatinib yielded a hematologic response in 82% of patients (sustained in 69% and complete in 34%) and major cytogenetic response in 24% (complete in 17%).[6]

Sawyers et al found that among patients in myeloid blast crisis (260 patients) treatment with imatinib resulted in sustained hematologic responses lasting at least 4 weeks in 31% of patients, including complete hematologic responses in 8%. Major cytogenetic responses occurred in 16% of patients, with 7% of the responses being complete.[19]

For patients with chronic-phase CML, imatinib at 400 mg/day is the best candidate for primary therapy, because it induces a complete hematologic response in almost all patients and causes a high cytogenetic response rate.

A study in 1106 patients with newly diagnosed, chronic-phase CML concluded that in terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib is superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed, chronic-phase CML.[20] The estimated rates of complete cytogenetic response were 76.2% for the imatinib group and 14.5% in the interferon alfa group.[20]

The estimated rate of a major cytogenetic response at 18 months was 87.1% in the imatinib group and 34.7% in the group given interferon alfa plus cytarabine. At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7% in the imatinib group and 91.5% in the combination-therapy group. Imatinib was better tolerated than combination therapy.[20]

Molecular remission is the goal as measured by PCR. Continuation of the drug is important because approximately 20% of patients lose complete cytogenic response, at a rate of 1.4 per 100 person-years. This is due to poor adherence or poor tolerance of the drug in patients who had an adherence rate of less than 85% as the main reason for complete cytogenic response loss.[21]

Treatment of patients with CML in the accelerated phase or in blast crisis has yielded dismal results. Although imatinib can induce a hematologic response in 52-82% of patients, the response is sustained for at least 4 weeks in only 31-64% of patients. The complete response rate is lower, at 7-34% of patients. Karyotypic response occurs in 16-24%, and complete cytogenetic response is observed in only 17%.[19] Higher doses (ie, 600 mg/d) result in improved response rates, cytogenetic response, and disease-free and overall survival.

In Ph1-positive acute lymphoblastic leukemia (ALL), the combination of chemotherapy plus imatinib is associated with a 2-year survival rate of 60%.

Resistance of CML cells to imatinib is emerging through multiple mechanisms such as overexpression of BCR/ABL and mutations of the abl gene.[8, 9, 22] Resistance can be overcome by increasing the imatinib dose, by developing more selective bcr-abl kinase inhibitors, and developing new non–cross-resistant drugs.

The molecular mechanism for primary imatinib resistance is unknown. Kinase-domain mutations in BCR/ABL represent the most common mechanism of secondary or acquired resistance to imatinib, accounting for 50-90% of cases; 40 different mutations have currently been described. Because imatinib binds to the ABL kinase domain in the inactive, or closed, conformation to induce conformational changes, resistance occurs when the mutation prevents the kinase domain from adopting the specific conformation upon binding.

A study by Marcolino et al found that imatinib therapy introduced to non – clinical trial patients with CML was associated with potentially irreversible acute renal injury; long-term treatment may cause a clinically relevant decrease in the estimated glomerular filtration rate (GFR).[23]


Newer Tyrosine Kinase Inhibitors

Newer BCR/ABL inhibitors, dasatinib (Sprycel), nilotinib (Tasigna), and bosutinib (Bosulif) are more potent inhibitors of BCR/ABL than imatinib. Moreover, they exhibit significant activity against all resistant mutations except the BCR/ABL/T315I mutation.

Dasatinib and nilotinib have been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Ph1+ chronic-phase CML, as well as for chronic-phase CML resistant or intolerant to prior therapy that included imatinib.[24, 25] Bosutinib was approved by the FDA in September 2012 for chronic-, accelerated-, or blast-phase Ph+ CML in patients resistant to or intolerant of other therapies, including imatinib.[26]

Jabbour and colleagues found that second-generation tyrosine kinase inhibitors induced higher rates of early complete cytogenic response (CCyR) and major molecular response than imatinib. The authors also state that CCyR is a major determinant of CML outcome, regardless of whether major molecular response is achieved or not.[27]

Compared with these next-generation agents, imatinib has relatively low potency and inhibits its target at micromolecular rather than nanomolar concentrations. In addition, imatinib has increased susceptibility to resistance through a number of mutations in the BCR-ABL target.[28]

That said, these new tyrosine kinase inhibitors are not without their drawbacks and adverse events. Dasatinib has been associated with pleural effusions and pulmonary arterial hypertension,[29] while nilotinib has been linked to biochemical changes in liver function and QT-interval prolongation. Development of resistance may also occur with these agents.

Moreover, imatinib is still very effective. It is also less expensive than the new tyrosine kinase inhbitors, and will go out of patent in the near future. Consequently, it may survive the challenge posed by newer agents because of a favorable balance of cost and efficacy.[30] Using the MD Anderson prognostic factors scoring may help in identifying the few patients requiring the more expensive second-generation tyrosine kinase inhibitors for first-line use.[31]

A study by Verma et al found that second malignancies occur in a small percentage of patients receiving tyrosine kinase inhibitor treatment for hematologic malignancies, mostly CML. No evidence suggests, however, that exposure to these inhibitors increases the risk of developing second malignancies.[32]


Dasatinib has been shown to be more effective in inducing molecular remission than imatinib. In a comparison of dasatinib with imatinib in 519 patients with newly diagnosed chronic-phase CML, the rate of confirmed complete cytogenetic response after a minimum follow-up of 12 months was 77% with dasatinib versus 66% with imatinib.[33]

A study by Cortes et al that compared dasatinib 100 mg daily or 50 mg twice daily for at least 3 months as initial therapy for early chronic-phase CML found no difference in outcome between the 2 dosages.[34] Of the 50 patients in the study, 49 (98%) achieved a complete cytogenetic response and 41 (82%) achieved a major molecular response. The projected event-free survival rate at 24 months was 88%, and all patients were alive after a median follow-up time of 24 months.[34]

In June 2013, the FDA approved a change to the product labeling of dasatinib, updating efficacy and safety information to include 3-year efficacy and safety data for patients with newly diagnosed Philadelphia (Ph) chromosome–positive CML that is in the chronic phase.[35] The new labeling also includes 5-year data for patients with chronic-phase Ph chromosome–positive CML that is imatinib-resistant or imatinib-intolerant.

The 3-year data are from the DASISION (Dasatinib vs Imatinib Study in Treatment-Naïve CML Patients) study, an ongoing open-label randomized phase 3 trial.[36] At 12 months, the confirmed cytogenetic response rate (CCyR) was 77% in patients treated with dasatinib and 66% in those treated with imatinib. At 36 months, a higher percentage of patients in the dasatinib group had confirmed CCyR (83% vs 77%). The rate of major molecular response (MMR) was also higher for dasatinib at both 12 and 36 months.

The 5-year data are from an open-label phase 3 dose-optimization study in which fewer than 5% of dasatinib patients had transformed to accelerated or blast-phase CML by 5 years.[35] The primary endpoint of the study was major cytogenetic response in patients who were resistant to or intolerant of imatinib. This endpoint was achieved by 63% of such patients who were receiving dasatinib at 2 years.

In a study of 670 patients with imatinib-resistant/-intolerant CML in chronic phase, Shah et al found that treatment with dasatinib (in 4 different regimens) improved survival, particularly among those who achieved BCR/ABL transcripts of 10% or less by 3 months.[37]

Estimated 6-year progression-free survival (PFS) rates were 49%, 51%, 40%, and 47% for the 100 mg once daily, 50 mg twice daily, 140 mg once daily, and 70 mg twice daily dosage groups, respectively.[37] Notably, estimated 6-year PFS rates were 68% for BCR/ABL transcripts of 1% or less, 58% for BCR/ABL greater than 1% up to 10%, and 26% for BCR/ABL greater than 10%. Estimated 6-year overall survival rates were 71% for 100 mg once daily, 74% for 50 mg twice daily, 77% for 140 mg once daily, and 70% for 70 mg twice daily.


Nilotinib has been found superior to imatinib in patients with newly diagnosed chronic-phase Ph+ CML.[38] In addition, Kantarjian et al reported that nilotinib maintained better efficacy during a minimum follow-up of 24 months. Compared with imatinib, significantly more patients receiving nilotinib achieved a major molecular response, or a complete molecular response at any time, and fewer progressed to accelerated or blast phase. These authors concluded that these results support the use of nilotinib as a first-line treatment option.[39]


Approval of bosutinib was based on a single-arm, open-label, multicohort, phase I/II study of more than 500 patients with imatinib-resistant or -intolerant Ph+ CML. Separate cohorts were established for chronic-, accelerated-, and blast- phase CML previously treated with 1 or more prior tyrosine kinase inhibitors (ie, imatinib, imatinib followed by dasatinib and/or nilotinib).

In 118 patients with chronic-phase CML, a major cytogenetic response was attained in 32% of patients, a complete cytogenetic response was attained in 24%, and a complete hematologic response was attained in 73%. At 2 years, the progression-free survival rate was 73% and the estimated overall survival rate was 83%. Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I.[40]


Ponatinib (Iclusig) was approved by the FDA in December 2012 for use in patients with CML that had relapsed or become refractory to other therapies. Many of these patients will have developed a T315I mutation, which confers resistance to imatinib and other tyrosine kinase inhibitors.[41, 42, 43]

In the phase 2 PACE (Ponatinib PH+ ALL [acute lymphoblastic leukemia] and CML Evaluation) trial, the drug successfully treated patients with chronic-phase CML (major cytogenetic response in 55% of cases, including 70% of patients with the T315I mutation, within 12 months), with accelerated-phase CML (major hematologic response in 57% of cases within 6 months), or with blast-phase CML/Ph1-positive ALL (major hematologic response in 34% of cases within 6 months).[41, 42, 43]

In October 2013, at the FDA’s request, ponatinib was temporarily removed from the market because of safety concerns. The FDA cited an increased risk for life-threatening blood clots and severe narrowing of blood vessels.[44, 45] In December 2013, the FDA allowed resumption of marketing, since the benefits of response to ponatinib far outweigh the risk of complications from the drug.[46, 47]

However, the FDA required the addition of a black box warning regarding arterial and venous thrombosis and occlusions, which have occurred in at least 27% of patients in early trials, typically within 2 weeks of starting ponatinib. In addition, the FDA limited the indications for use of ponatinib to the following[47] :

  • Adult patients with T315I -positive CML in chronic, accelerated, or blast phase (or T315I -positive, Ph1-positive ALL)
  • Adult patients with chronic, accelerated, or blast phase CML for whom no other TKI therapy is indicated

The FDA has also revised the dosing recommendations to state that the optimal dose of ponatinib has not been identified. The recommended starting dose remains 45 mg once daily, but additional information is included regarding dose decreases and discontinuations.

The author agrees that the FDA acted appropriately in limiting the use of ponatinib but making it available from the market while experts determine the optimal dose and dosing schedule for lessening toxicity from ponatinib without compromising its efficacy. This is a process that many other agents have had to undergo, following FDA approval. The T315I mutation for which ponatinib is effective is very rare, affecting only a small minority of CML patients. Nevertheless, for some of those patients, ponatinib has proved lifesaving.


Protein Translation Inhibitors

In October 2012, the US Food and Drug Administration (FDA) approved omacetaxine (Synribo). Omacetaxine is a protein translation inhibitor that is indicated for chronic- or accelerated-phase CML with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors (TKIs) (eg, dasatinib, nilotinib, imatinib).

Approval was based on combined data from 2 phase 2, open-label, multicenter studies. Pooled data included patients (n=111) who had received two or more TKIs and showed evidence of resistance or intolerance. In patients with chronic-phase CML taking omacetaxine, 18% attained a major cytogenetic response (MCyR) (mean time to MCyR onset, 3.5 mo). The median duration of MCyR was 12.5 months. Of patients with accelerated-phase CML who received omacetaxine, 14% attained a major hematologic response (MaHR); mean time to MaHR was 2.3 mo and mean duration of MaHR was 4.7 months.[48]


Myelosuppressive Therapy

Myelosuppressive therapy was formerly the mainstay of treatment to convert a patient with CML from an uncontrolled initial presentation to one with hematologic remission and normalization of the physical examination and laboratory findings. However, it may soon fall out of favor as the new agents prove to be more effective, with fewer adverse events and longer survival.


Hydroxyurea (Hydrea), an inhibitor of deoxynucleotide synthesis, is the most common myelosuppressive agent used to achieve hematologic remission. The initial blood cell count is monitored every 2-4 weeks, and the dose is adjusted depending on the WBC and platelet counts. Most patients achieve hematologic remission within 1-2 months.

This medication causes only a short duration of myelosuppression; thus, even if the counts go lower than intended, stopping treatment or decreasing the dose usually controls the blood counts. Maintenance with hydroxyurea rarely results in cytogenetic or molecular remissions.


Busulfan (Myleran) is an alkylating agent that has traditionally been used to keep the WBC counts below 15,000 cells/µL. However, the myelosuppressive effects may occur much later and persist longer, which makes maintaining the numbers within normal limits more difficult. Long-term use can cause pulmonary fibrosis, hyperpigmentation, and prolonged marrow suppression lasting for months.



Leukapheresis using a cell separator can lower WBC counts rapidly and safely in patients with WBC counts greater than 300,000 cells/µL, and it can alleviate acute symptoms of leukostasis, hyperviscosity, and tissue infiltration.

Leukapheresis usually reduces the WBC count only temporarily. Thus, it is often combined with cytoreductive chemotherapy for more lasting effects.


Interferon alfa

In the past, interferon alfa was the treatment of choice for most patients with CML who were too old for bone marrow transplantation (BMT) or who did not have a matched bone marrow donor. With the advent of tyrosine kinase inhibitors, interferon alfa is no longer considered first-line therapy for CML. It may be used in combination with newer drugs for treatment of refractory cases.

A study by Simonsson et al found that the addition of even relatively short periods of pegylated interferon alfa2b to imatinib increased the major molecular response rate at 12 months of therapy. Lower doses of pegylated interferon alfa2b may enhance tolerability while retaining efficacy and could be considered in future studies.[49]



Allogeneic bone marrow transplantation (BMT) or stem cell transplantation is currently the only proven cure for CML. Ideally, it should be performed in the chronic phase of the disease rather than in the transformation phase or in blast crisis. Candidate patients should be offered the procedure if they have a matched or single–antigen-mismatched related donor available. In general, younger patients fare better than older patients.

BMT should be considered early in young patients (< 55 y) who have a matched sibling donor.[50, 51] All siblings should be typed for human leukocyte antigen (HLA)-A, HLA-B, and HLA-DR. If no match is available, the HLA type can be entered into a bone marrow registry for a completely matched unrelated donor.

Allogeneic BMT with matched unrelated donors has yielded very encouraging results in this disease. The procedure has a higher rate of early and late graft failures (16%), grade III-IV acute graft versus host disease (50%), and extensive chronic graft versus host disease (55%). The overall survival rate ranges from 31% to 43% for patients younger than 30 years and from 14% to 27% for older patients. Benefits and risks should be assessed carefully with each patient.

The mortality rate associated with BMT is 10-20% or less with a matched sibling and 30-40% with an unrelated donor. The bone marrow registry approximates the cure rate for patients with CML at 50%.

Transplantation has been relegated to patients who do not achieve molecular remissions or show resistance to imatinib and failure of second-generation bcr-abl kinase inhibitors such as dasatinib. Previous exposure to imatinib before transplantation does not adversely affect posttransplant outcomes such as overall survival and progression-free survival.

A retrospective analysis that included 70 patients with CML (44% in accelerated phase or blast crisis) who had received imatinib before stem cell transplantation showed 90% engraftment and estimated transplant-related mortality of 44% and estimated relapse mortality of 24% at 24 months. Graft versus host disease rates were 42% for acute and 17% for chronic.[52]

Most data are from allogeneic transplantations from HLA-matched sibling donors and a few syngeneic transplantations from an identical twin. Data show that allogeneic transplantations have better results than syngeneic transplantations because of some graft versus leukemia effects.

Autologous BMT is investigational, but, relatively recently, chemotherapy combinations or interferon have been found to induce a cytogenetic remission and allow harvesting of Ph-negative CD34 hematopoietic stem cells from the patient's peripheral blood.

The advent of imatinib therapy has overshadowed allogeneic hematopoietic stem cell transplantation in newly diagnosed CML. However, it has been suggested that patients with a poor-risk Sokal score (see Prognosis) but good risk for allogeneic hematopoietic stem cell transplantation be transplanted early or upfront. No current consensus exists on these issues. However, a widely accepted consensus is that patients who progress beyond chronic phase on imatinib should be offered hematopoietic stem cell transplantation if this is an option.

With patients in blast crisis who are imatinib naive, the drug is used in combination with induction regimens similar to those used in acute myelogenous or lymphoblastic leukemia. However, because a high percentage of imatinib-resistant mutations exist in these patients, relapses occur more frequently and at an earlier time from induction. Thus, all efforts are made to perform an allogeneic hematopoietic stem cell transplantation as soon as possible.

Most patients with minimal residual disease (MRD) after transplantation require interferon maintenance therapy. Alternatively, they may require a reinfusion of T cells collected from the donor.



Splenectomy and splenic irradiation have been used in patients with large and painful spleens, usually in the late phase of CML. This is rarely needed in patients whose disease is well controlled.

Some authors believe that splenectomy accelerates the onset of myeloid metaplasia in the liver. In addition, splenectomy is associated with high perioperative morbidity and mortality rates because of bleeding or thrombotic complications.


Long-Term Monitoring

The cytogenetic response is monitored every 3-6 months by karyotyping or by fluorescence in situ hybridization (FISH) to count the percentage of bone marrow cells with Ph1-positive cells in bone marrow. Long-term monitoring using peripheral blood for FISH and quantitative reverse transcriptase PCR (RT-PCR) for BCR/ABL messenger RNA appear to be reliable methods for monitoring responses to tyrosine kinase inhibitor therapy in all phases of CML.[53]

The goal is 100% normal cells after 1-2 years of therapy. Patients with MRD (BCR/ABL positive) should be kept on maintenance therapy as long as they continue to have MRD.

Cytogenetic improvement has been observed in 70% of patients treated for longer than 3 months, with the median of Ph1-positive cells declining from 100% to 65% (range 0-95%). Complete suppression of the Ph1 chromosome was observed in 20% of patients.

More than 80% of newly diagnosed patients with CML in the chronic phase will achieve a complete cytogenetic response with the standard dose of 400 mg/day of imatinib. The probability of progression-free survival is strongly correlated with the level of response, approaching 100% in those patients who achieve molecular remission (a reduction of BCR/ABL mRNA by at least 3-log at 12 mo).

In patients with chronic-phase CML whose interferon therapy had failed, the complete cytogenetic response was 41% at 18 months and 52% at 40 months, with a progression-free survival at 2 years of 76%. Progression to an accelerated phase or blast crisis had a peak at 2 years of 7.6%, but the incidence remained constant over the years at an average of 2%.

High Sokal risk predicts poorer outcome, but responses during treatment generally override pretherapeutic prognostic variables. When less-sensitive tests become negative, more-sensitive tests are done (ie, cytogenetics and FISH); thus, monitoring should be tailored to the level of response attained by a given patient.

The standard therapeutic milestones to be achieved are as follows:

  1. At 3 months: complete hematologic response (normal complete blood count and no evidence of extramedullary disease)
  2. At 6 months: minor cytogenetic response (36% to 65% of cells Ph1+)
  3. At 12 months: major cytogenetic response (0% to 35% Ph1+)
  4. At 18 months: complete cytogenetic response (0% Ph1+)

Failure to achieve these milestones should trigger a reassessment of the therapeutic strategy. Most patients with complete cytogenetic response continue to have positive RT-PCR findings, indicating the presence of MRD. Discontinuation of the drug in these patients is usually followed by relapse, suggesting that imatinib fails to eradicate leukemic stem cells in these patients.

Early intensification with the use of high doses of imatinib (800 mg/d) or imatinib in combination with cytarabine or interferon alfa may induce higher rates of RT-PCR negativity, but this needs to be confirmed in further studies.

The criteria for major molecular response is ≥3-log reduction of BCR/ABL mRNA, and for complete molecular response it is negativity by RT-PCR. Because a good correlation exists between BCR/ABL mRNA in bone marrow and peripheral blood, this can be monitored from peripheral blood samples.

At 12 months with complete cytogenetic response, patients can be classified according to their molecular response into those with major molecular response (≥3-log) or < 3-log reduction of transcripts (98% vs 90% progression-free survival).

Limited data are available on patients with complete cytogenetic response or major molecular response who discontinued their treatment with imatinib (5 of 6 patients had reappearance of Ph+).

Patients should be screened for mutations of the BCR/ABL kinase domain whenever there is an indication of loss of response to imatinib at any level. Primary hematologic resistance to imatinib occurs in approximately 5% of patients who fail to achieve complete histologic remission, and 15% show primary cytogenetic resistance in the chronic phase. Secondary or acquired resistance (loss of previous response) is 16% at 42 months and increases to 26% in those previously treated with interferon, and is 73-95% in the accelerated or blast phase.

Contributor Information and Disclosures

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Chief Editor

Koyamangalath Krishnan, MD, FRCP, FACP Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.


Bruce Buehler, MD Professor, Department of Pediatrics and Genetics, Director RSA, University of Nebraska Medical Center

Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association

Disclosure: Nothing to disclose.

Maurie Markman, MD Vice President for Medical Oncology Services, National Director for Medical Oncology, Cancer Treatment Centers of America

Maurie Markman, MD is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Clinical Oncology, and American Society of Hematology

Disclosure: Eli Lilly Honoraria Speaking and teaching; Genentech Consulting fee Consulting; Cellgene Consulting fee Consulting; Hana Pharmaceuticals Consulting fee Consulting; Boehringer Ingelheim Consulting fee Consulting; Ortho Biotech Consulting fee Consulting; Morphotech Consulting; Amgen Consulting fee Consulting

Ronald A Sacher, MB, BCh, MD, FRCPC Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Clinical and Climatological Association, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society of Blood Transfusion, International Society on Thrombosis and Haemostasis, and Royal College of Physicians and Surgeons of Canada

Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

Clarence Sarkodee-Adoo, MD Consulting Staff, Department of Bone Marrow Transplantation, City of Hope Samaritan BMT Program

Disclosure: Takeda Millenium Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

  1. PDQ Adult Treatment Editorial Board. Chronic Myelogenous Leukemia Treatment (PDQ®): Health Professional Version. March 9, 2016. [Medline]. [Full Text].

  2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999 Apr 29. 340(17):1330-40. [Medline].

  3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001 Apr 5. 344(14):1038-42. [Medline]. [Full Text].

  4. Kantarjian H, Sawyers C, Hochhaus A, et al, for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28. 346(9):645-52. [Medline]. [Full Text].

  5. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002 Sep. 16(9):1579-83. [Medline]. [Full Text].

  6. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Mar 15. 99(6):1928-37. [Medline]. [Full Text].

  7. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003 Jan 1. 101(1):97-100. [Medline]. [Full Text].

  8. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16. 305(5682):399-401. [Medline].

  9. Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett. 2009 Feb 8. 274(1):1-9. [Medline].

  10. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15. 341(3):164-72. [Medline].

  11. Cancer Facts & Figures 2016. American Cancer Society. Available at Accessed: April 14, 2016.

  12. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M al et. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr 6. 103(7):553-61. [Medline].

  13. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 Mar 22. [Medline].

  14. PDQ Adult Treatment Editorial Board. Chronic Myelogenous Leukemia Treatment (PDQ®): Patient Version. 2002. [Medline]. [Full Text].

  15. Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015 May 21. 125 (21):3230-5. [Medline].

  16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5. 344(14):1031-7. [Medline]. [Full Text].

  17. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001 Oct 1. 98(7):2039-42. [Medline]. [Full Text].

  18. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011 Mar 1. 117(5):982-91. [Medline].

  19. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15. 99(10):3530-9. [Medline].

  20. Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11. 118(6):1622-31. [Medline].

  21. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011 Apr 7. 117(14):3733-6. [Medline].

  22. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002 Nov. 16(11):2190-6. [Medline].

  23. Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011 Sep. 22(9):2073-9. [Medline].

  24. FDA Approval for Dasatinib. National Cancer Institute. Available at Accessed: October 8, 2015.

  25. FDA Approval for Nilotinib. National Cancer Institute. Available at Accessed: October 8, 2015.

  26. Bosulif (bosutinib) [package insert]. New York, NY: Pfizer, Inc. April 2016. Available at [Full Text].

  27. Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27. 118(17):4541-6; quiz 4759. [Medline].

  28. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11. 116(19):3758-65. [Medline].

  29. FDA. Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension. US Food and Drug Administration. Available at Accessed: October 8, 2015.

  30. Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med. 2010 Jun 17. 362(24):2314-5. [Medline].

  31. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, et al. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood. 2010 Oct 28. [Medline].

  32. Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20. 118(16):4353-8. [Medline].

  33. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17. 362(24):2260-70. [Medline].

  34. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20. 28(3):398-404. [Medline]. [Full Text].

  35. Mulcahy N. FDA updates dasatinib label for chronic myeloid leukemia. Medscape Medical News. June 26, 2013. [Full Text].

  36. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23. 123 (4):494-500. [Medline]. [Full Text].

  37. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood. 2014 Feb 25. [Medline].

  38. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17. 362(24):2251-9. [Medline].

  39. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep. 12(9):841-51. [Medline].

  40. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12. 119(15):3403-12. [Medline].

  41. Chustecka Z. FDA Approves Ponatinib for Rare Leukemias. Medscape Medical News. December 14, 2012. [Full Text].

  42. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29. 367(22):2075-88. [Medline].

  43. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7. 369 (19):1783-96. [Medline].

  44. Mulahy N. Leukemia Drug Ponatinib (Iclusig) Pulled From Market. Medscape Medical News. Available at Accessed: October 8, 2015.

  45. FDA Drug Safety Communication. FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. US Food and Drug Administration. Available at Accessed: October 8, 2015.

  46. Nelson R. Ponatinib (Iclusig) Returns to Market, With a Few Caveats. Medscape Medical News. Available at Accessed: October 8, 2015.

  47. FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. US Food and Drug Administration. Available at Accessed: October 8, 2015.

  48. Synribo (omacetaxine) [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc. October, 2012. Available at [Full Text].

  49. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-a2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011 Sep 22. 118(12):3228-35. [Medline].

  50. Moreb J, Johnson T, Kubilis P, Myers L, Oblon D, Miller A, et al. Improved survival of patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation. Am J Hematol. 1995 Dec. 50(4):304-6. [Medline].

  51. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood. 1990 Apr 15. 75(8):1728-32. [Medline].

  52. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006 Apr. 91(4):452-9. [Medline].

  53. Lima L, Bernal-Mizrachi L, Saxe D, Mann KP, Tighiouart M, Arellano M, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer. 2011 Mar 15. 117(6):1245-52. [Medline].

Blood film at 400X magnification demonstrates leukocytosis with the presence of precursor cells of the myeloid lineage. In addition, basophilia, eosinophilia, and thrombocytosis can be seen. Courtesy of U. Woermann, MD, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland.
Blood film at 1000X magnification demonstrates the whole granulocytic lineage, including an eosinophil and a basophil. Courtesy of U. Woermann, MD, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland.
Blood film at 1000X magnification shows a promyelocyte, an eosinophil, and 3 basophils. Courtesy of U. Woermann, MD, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland.
Bone marrow film at 400X magnification demonstrates clear dominance of granulopoiesis. The number of eosinophils and megakaryocytes is increased. Courtesy of U. Woermann, MD, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland.
The Philadelphia chromosome, which is a diagnostic karyotypic abnormality for chronic myelogenous leukemia, is shown in this picture of the banded chromosomes 9 and 22. Shown is the result of the reciprocal translocation of 22q to the lower arm of 9 and 9q (c-abl to a specific breakpoint cluster region [bcr] of chromosome 22 indicated by the arrows). Courtesy of Peter C. Nowell, MD, Department of Pathology and Clinical Laboratory of the University of Pennsylvania School of Medicine.
Fluorescence in situ hybridization using unique-sequence, double-fusion DNA probes for bcr (22q11.2) in red and c-abl (9q34) gene regions in green. The abnormal bcr/abl fusion present in Philadelphia chromosome–positive cells is in yellow (right panel) compared with a control (left panel). Courtesy of Emmanuel C. Besa, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.